Developing a new drug costs $2.23 billion on average in 2024, up from $2.12 billion the year before, according to Deloitte’s annual report on pharmaceutical R&D returns. While the FDA has streamlined its review process—approving 50 new drugs in 2024 with an average review time of just 10 months for standard applications—much of the development timeline isn’t spent in trials or regulatory review. It’s consumed by the painstaking process of finding, integrating, and preparing data for regulatory submission.

The bottleneck lies squarely with Regulatory Compliance teams, who must synthesize massive volumes of data from clinical trials, Chemistry, Manufacturing, and Controls (CMC) processes, and post-market surveillance. To generate a complete regulatory submission package, these teams navigate a maze of disconnected systems—Laboratory Information Management Systems (LIMS), Enterprise Resource Planning (ERP) platforms, and Manufacturing Execution Systems (MES)—each speaking its own data language.

The Data Integration Crisis

Every system in the drug development ecosystem optimizes for specific functions, yet they rarely share common vocabularies. Analytical testing results, operational procedures, and manufacturing batch records exist in proprietary formats, creating barriers that demand extensive manual reconciliation.

Data engineering teams spend months massaging, transforming, and connecting information before Reporting and Analytics can produce regulatory-ready documentation. This process isn’t just time-consuming—it’s error-prone. The FDA issued over 160 Warning Letters citing data integrity deficiencies between 2017 and 2022, and continues to emphasize ALCOA principles (Attributable, Legible, Contemporaneous, Original, Accurate) as foundational requirements.

With 57% of 2024 FDA approvals using expedited pathways like Breakthrough Therapy or Fast Track designations, the pressure to move quickly while maintaining impeccable data integrity has never been greater.

Semantic Technology: From Data Silos to Connected Knowledge

Semantic data technology offers a fundamentally different approach. Rather than forcing manual integration, semantic platforms use machine learning to scan, label, and automatically classify data from LIMS, ERP, and MES systems against industry-standard ontologies—formalized vocabularies that regulatory agencies already recognize and expect.

The Allotrope Foundation, an international consortium of pharmaceutical and biopharmaceutical companies, has developed ontologies specifically for laboratory analytical processes. Standards like ISA-88 for batch control and the FDA’s Electronic Common Technical Document (eCTD) provide the semantic scaffolding for regulatory submissions. When data is tagged according to these frameworks, it becomes inherently submission-ready.

The transformative power lies in in-place integration. Data doesn’t need to be physically moved into a centralized location. Instead, semantic queries traverse connected systems, linking and analyzing information wherever it resides. For Regulatory Compliance teams, this means generating required reports, charts, and evidence tables directly from source data—dramatically reducing both timelines and error rates.

Knowledge Graphs: The Foundation for AI-Ready Compliance

As pharmaceutical companies increasingly explore AI and Large Language Models for regulatory intelligence, the quality of underlying data becomes critical. Research shows that knowledge graphs significantly outperform traditional relational databases in AI accuracy tasks. Centralized relational data achieves roughly 80% accuracy even with extensive integration work. Semantic knowledge graphs push that ceiling to 95%+ with decentralized architectures enabling near-perfect accuracy on complex queries.

For pharmaceutical companies, this accuracy gap is existential. When regulatory submissions must be precise and comprehensive, an 80% accuracy ceiling isn’t acceptable. The 2025 FDA draft guidance on AI in drug development emphasizes credibility assessment frameworks that demand transparency and traceability—exactly what semantic knowledge graphs provide through built-in data lineage and provenance.

Building a Reusable Drug Manufacturing Knowledge Asset

Perhaps the most compelling benefit of semantic data technology is its compound value over time. Once a Drug Manufacturing Knowledge Asset is constructed—integrating data from compounds, analytical tests, operational processes, and manufacturing batches—it serves as a reusable foundation for future drug development programs.

This one-time investment pays ongoing dividends. Instead of starting from scratch for each regulatory submission, teams leverage pre-existing semantic structures, applying them to new compounds and formulations. What traditionally consumed six to nine months of data preparation can be compressed significantly—potentially shaving months off regulatory timelines for subsequent drug programs.

The Path Forward

The pharmaceutical industry stands at an inflection point. Deloitte’s analysis shows R&D returns rose to 5.9% in 2024 (up from 4.3% in 2023), driven partly by efficiency improvements and the emergence of high-value therapeutics like GLP-1 drugs. Yet the $7.7 billion spent on terminated trials in 2024 alone underscores how much value remains trapped in fragmented data ecosystems.

Semantic data technology—built on industry standards like Allotrope ontologies, aligned with regulatory frameworks like eCTD, and capable of achieving the accuracy thresholds that AI-powered compliance demands—offers a sustainable path forward. Organizations can pilot these approaches within 90 days, connecting sample LIMS and ERP data sources to demonstrate proof of concept before broader deployment.

In an industry where time literally translates to lives saved, the ability to compress regulatory timelines while maintaining—or improving—data integrity represents an invaluable competitive advantage. The technology exists today. The question is which organizations will seize it first.

Ready to explore how semantic data technology can accelerate your regulatory timelines? Fluree’s platform integrates clinical trial data, regulatory documentation, and compliance requirements into a unified knowledge graph—with built-in security policies that ensure confidentiality and governance from day one. Contact us to discuss a pilot program for your organization.